{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:49:35Z","timestamp":1765374575027,"version":"3.46.0"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chronic Disease Management Research Project of National Health Commission Capacity Building and Continuing Education Center","award":["GWJJMB202510022168"],"award-info":[{"award-number":["GWJJMB202510022168"]}]},{"name":"Medical Science and Technology Research Project of Henan Province","award":["LHGJ20240257"],"award-info":[{"award-number":["LHGJ20240257"]}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["252102311151"],"award-info":[{"award-number":["252102311151"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Chronic obstructive pulmonary disease (COPD) is a major global health burden. The fluticasone furoate (FF)\/umeclidinium (UMEC)\/vilanterol (VI) triple therapy provides new treatment, but its long-term real-world safety lacks evidence. A post-marketing analysis used the FAERS database to identify adverse event (AE) signals for FF\/UMEC\/VI. Disproportionality methods including reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM), were applied to detect AE signals, focusing on reports from third quarter (Q3) 2019 to Q3 2024. Among 16,238 reports listing FF\/UMEC\/VI as primary suspect, significant AE signals occurred in \u2018injury, poisoning and procedural complications\u2019 (n = 9067, ROR 2.46, PRR 2.08, IC 1.06, EBGM 2.08), and \u2018respiratory, thoracic and mediastinal disorders\u2019 (n = 6567, ROR 4.87, PRR 4.15, IC 2.05, EBGM 4.13). A total of 196 significantly disproportionate preferred terms (PTs) were identified, including previously undocumented AEs such as chronic eosinophilic rhinosinusitis, dysphonia, and vocal cord dysfunction. This post-marketing safety study revealed significant signals for dysphonia and vocal cord dysfunction associated with FF\/UMEC\/VI, suggesting that clinicians should remain vigilant for these events.<\/jats:p>","DOI":"10.3390\/pharmacy13060178","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:20:57Z","timestamp":1765369257000},"page":"178","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mining of Adverse Event Signals Associated with Fluticasone Furoate\/Umeclidinium\/Vilanterol Triple Therapy: A Post-Marketing Analysis Based on FAERS"],"prefix":"10.3390","volume":"13","author":[{"given":"Jiajun","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Services, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaoxing","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-2957","authenticated-orcid":false,"given":"Xiaocan","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jicun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-med-080919-112707","article-title":"Advances in chronic obstructive pulmonary disease","volume":"72","author":"Ferrera","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","article-title":"Chronic obstructive pulmonary disease","volume":"399","author":"Christenson","year":"2022","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2147\/COPD.S369120","article-title":"Health inequality in the global burden of chronic obstructive pulmonary disease: Findings from the global burden of disease study 2019","volume":"17","author":"Li","year":"2022","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tranmer, J., Rotter, T., O\u2019Donnell, D., Marciniuk, D., Green, M., Kinsman, L., and Li, W. (2022). Determining the influence of the primary and specialist network of care on patient and system outcomes among patients with a new diagnosis of chronic obstructive pulmonary disease (COPD). BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08588-w"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pulmoe.2018.09.006","article-title":"COPD and cardiovascular disease","volume":"25","author":"Conde","year":"2019","journal-title":"Pulmonology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.chest.2022.11.003","article-title":"Preserved ratio impaired spirometry in relationship to cardiovascular outcomes","volume":"163","author":"Zheng","year":"2023","journal-title":"Chest"},{"key":"ref_7","first-page":"434","article-title":"The diagnosis and treatment of COPD and its comorbidities","volume":"120","author":"Kahnert","year":"2023","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2015.05.020","article-title":"Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy","volume":"761","author":"Calzetta","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_9","first-page":"1","article-title":"Triple therapy for COPD: A crude analysis from a systematic review of the evidence","volume":"13","author":"Soriano","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"00061-2019","DOI":"10.1183\/23120541.00061-2019","article-title":"Clinical effectiveness of once-daily fluticasone furoate\/umeclidinium\/vilanterol in usual practice: The COPD INTREPID study design","volume":"5","author":"Worsley","year":"2019","journal-title":"ERJ Open Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","article-title":"Fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis","volume":"39","author":"Ismaila","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/COPD.S427770","article-title":"Real-world effectiveness of fluticasone furoate\/umeclidinium\/vilanterol once-daily single-inhaler triple therapy for symptomatic COPD: The ELLITHE non-interventional trial","volume":"19","author":"Beeh","year":"2024","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41533-021-00241-z","article-title":"Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy versus tiotropium monotherapy in patients with COPD","volume":"31","author":"Bansal","year":"2021","journal-title":"Npj Prim. Care Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhou, C., Liu, Y., Hao, Y., Wang, J., Song, B., and Yu, J. (2024). Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1472648"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data Mining of the Public Version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/14740338.2024.2409707","article-title":"Mining of adverse event signals associated with inclisiran: A post-marketing analysis based on FAERS","volume":"24","author":"Shi","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2147\/COPD.S433326","article-title":"A long-term study of adverse outcomes associated with oral corticosteroid use in COPD","volume":"18","author":"Tse","year":"2023","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12931-020-01360-w","article-title":"Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: Lung function and health status results from two replicate randomized controlled trials","volume":"21","author":"Ferguson","year":"2020","journal-title":"Respir. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4187\/respcare.10188","article-title":"Therapeutic response to single-inhaler triple therapies in moderate-to-severe COPD","volume":"68","author":"Ohtsuka","year":"2023","journal-title":"Respir. Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: Analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/resp.14339","article-title":"Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial","volume":"27","author":"Thompson","year":"2022","journal-title":"Respirology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"00480","DOI":"10.1183\/23120541.00480-2020","article-title":"Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK","volume":"7","author":"Fenwick","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Shin, S., Ye, M., Park, J., and Geum, S. (2022). Immunopathologic role of eosinophils in eosinophilic chronic rhinosinusitis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113313"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.anl.2023.08.002","article-title":"The current findings in eosinophilic chronic rhinosinusitis","volume":"51","author":"Tsuda","year":"2024","journal-title":"Auris Nasus Larynx"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.anl.2017.12.002","article-title":"Is insufficient pulmonary air support the cause of dysphonia in chronic obstructive pulmonary disease?","volume":"45","author":"Hassan","year":"2018","journal-title":"Auris Nasus Larynx"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/ohn.198","article-title":"Voice disorders associated with the use of inhaled corticosteroids","volume":"168","author":"Naunheim","year":"2023","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/00002018-200629080-00003","article-title":"Pharmacovigilance during the pre-approval phases: An evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA\/CHMP risk-management guidelines","volume":"29","author":"Hartford","year":"2006","journal-title":"Drug Saf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0022-3859.93260","article-title":"Fluticasone furoate: A new intranasal corticosteroid","volume":"58","author":"Kumar","year":"2012","journal-title":"J. Postgrad. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.pupt.2012.12.001","article-title":"Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD","volume":"26","author":"Kempsford","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2040622317700822","article-title":"Umeclidinium in chronic obstructive pulmonary disease: Latest evidence and place in therapy","volume":"8","author":"Babu","year":"2017","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2147\/JAA.S424055","article-title":"Real-world study of single-inhaler triple therapy with fluticasone furoate\/umeclidinium\/vilanterol on asthma control in the US","volume":"16","author":"Bogart","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/JAA.S305918","article-title":"Safety of once-daily single-inhaler triple therapy with fluticasone furoate\/umeclidinium\/vilanterol in Japanese patients with asthma: A long-term (52-week) phase III open-label study","volume":"14","author":"Hozawa","year":"2021","journal-title":"J. Asthma Allergy"}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/178\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:54:22Z","timestamp":1765371262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pharmacy13060178"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13060178","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}